PIPELINE

Based on innovative scientific achievements,
Pimedbio's first-in-class drugs
  • home
  • Pipeline
  • Overview

Overview

First-in-class drug candidates to address unmet medical needs.

Oncology
Programs
Target analysis
& Lead design
Hit·Lead discovery
Candidate discovery
Non-clinical studies
& IND filing
Clinical studies
Cancer stemness blocking agent
(PMB212)
The 3rd-Generation Immuno-oncology therapeutics
Bispecific small molecule : BSM
Inhibitor-drug conjugates : IDC
Immunology
Programs
Target analysis
& Lead design
Hit·Lead discovery
Candidate discovery
Non-clinical studies
& IND filing
Clinical studies
Novel IBD
therapeutics
(PMB702)